Vnitr Lek 2016, 62(7-8):613-615

Possibilities of influencing cardiovascular risk in type 2 diabetes mellitus by antidiabetic treatment. Lowering of cardiovascular risk in treatment with liraglutide - Results of the LEADER

Jindřich Olšovský
II. interní klinika LF MU a FN u sv. Anny v Brně

The article summarizes current knowledge about the possibilities for influencing the cardiovascular risk in treatment of type 2 diabetes, especially focusing on the results of a prospective morbidity-mortality LEADER trial, which demonstrated the superiority of liraglutide in patients with very high cardiovascular risk.

Keywords: cardiovascular risk; LEADER; liraglutid; type 2 diabetes mellitus

Received: August 10, 2016; Accepted: August 17, 2016; Published: July 1, 2016  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Olšovský J. Possibilities of influencing cardiovascular risk in type 2 diabetes mellitus by antidiabetic treatment. Lowering of cardiovascular risk in treatment with liraglutide - Results of the LEADER. Vnitr Lek. 2016;62(7-8):613-615.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Nissen SE, Wolski K. Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch Int 2010; 170(14): 1191-1201. Go to original source... Go to PubMed...
    2. Gilbert RE, Mann JF, Hanefeld M et al. Basal insulin glargine and microvascular outcomes in dysglycaemic individuals: results of the Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial. Diabetologia 2014; 57(7): 1325-1331. Go to original source... Go to PubMed...
    3. Charbonnel B, Normandy J, Erdmann E et al. [PROactive Study Group]. The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients. Diabetes Care 2004; 27(7): 1647-1653. Go to original source... Go to PubMed...
    4. Scirica B, Braunwald E, Raz I et al. [SAVOR-TIMI 53 Steering Committee and Investigators]. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation 2014; 130(18): 1579-1588. Erratum in Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial. [Circulation. 2015]. Go to original source... Go to PubMed...
    5. White WB, Kupfer S, Zannad F et al. [EXAMINE Investigators]. Cardiovascular Mortality in Patients With Type 2 Diabetes and Recent Acute Coronary Syndromes From the EXAMINE Trial. Diabetes Care 2016; 39(7): 1267-1273. Go to original source... Go to PubMed...
    6. Green JB, Betel MA, Armstrong PW et al. [TECOS Study Group]. The Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2015; 373(3): 232-242. Go to original source... Go to PubMed...
    7. Pfeffer MA, Claggett B, Diaz R et al. [ELIXA Investigators]. Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. N Engl J Med 2015; 373(23): 2247-2257. Go to original source... Go to PubMed...
    8. Zinman B, Wanner Ch, Lachin JM et al.] EMPA-REG OUTCOME Investigators]. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 2015; 373(22): 2117-2128. Go to original source... Go to PubMed...
    9. Marso SP, Daniels GH, Brown-Frandsen K et al. [LEADER Steering Committee; LEADER Trial Investigators]. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2016; 375(4): 311-322. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.